ACCESS Newswire·Apr 16, 2026, 4:05 PM ET

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics issued inducement awards to two recently hired employees on April 15, 2026.
The awards included options to purchase 55,425 shares & restricted stock units for 14,425 shares.
The exercise price for the options was set at $105.44, based on the closing stock price on April 15, 2026.
Option shares vest over four years with 25% vesting on the first anniversary & the remainder in equal monthly installments.
RSU shares vest one-fourth annually over a four-year period.
The awards were approved by the compensation committee & granted under Nasdaq Marketplace Rule 5635(c)(4).
ICOTYDE is the first targeted oral peptide blocking the IL-23 receptor & is licensed to Janssen Biotech.
An NDA for rusfertide, co-developed with Takeda, is under priority FDA review.
Protagonist holds an option to co-commercialize rusfertide in the U.S. under a 50/50 profit & loss structure.